vivoVerse LLC (AKA: Newormics LLC) Profile last edited on: 3/3/2025
CAGE: 7HW06
UEI: DUQVP26ELTH5
Business Identifier: Optical and micro-technologies to advance early drug discovery 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
3303 Northland Drive Suite 308
Austin, TX 78731
Austin, TX 78731
| (650) 704-0764 |
| support@vivoverse.com |
| www.vivoverse.com |
Location: Single
Congr. District: 37
County: Travis
Congr. District: 37
County: Travis
Public Profile
To reflect our growing portfolio of products and services, Newormics LLC has rebranded to become vivoVerse LLC. vivoVerse specializes in developing cutting-edge automated microscopy systems and analytical tools for high-throughput biological research. By combining state-of-the-art imaging platforms with advanced computational models, vivoVerse empowers scientists to unlock new insights in developmental biology, toxicology, and beyond.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 1 | NIH | $287,021 | |
| Project Title: High-Content in vivo DNT Test Batteries using Cell-Specific Characterization of the Neurodevelopment and Synaptogenesis in C. elegans as NAMs | ||||
| 2024 | 2 | NIH | $2,092,117 | |
| Project Title: The Next-Generation Developmental and Reproductive Toxicology (DART) Assay using High-Content Analysis of Genetically Diverse C. elegans Populations | ||||
| 2022 | 2 | NIH | $2,523,071 | |
| Project Title: A Multiwell Plate Format Microfluidic Immobilization Chip for High-Content Imaging of Whole Animals | ||||
| 2019 | 1 | NIH | $222,780 | |
| Project Title: A Large-Scale Microfluidics Imaging Platform for High-Throughput Toxicity Testing using Canine Intestinal Organoids | ||||
| 0 | 1 | USDA | $175,000 | |
| Project Title: C. elegans Based Assay to Identify the Health Benefits and Toxicity of Food Ingredients | ||||
Key People / Management
Adela Ben-Yakar -- CEO and Co-Founder
Evan Hegarty -- Director of Manufacturing and Co-Founder
Adam Laing -- Scientist
Sudip Mondal
Shivang Sharma -- Tecnical Sales and Marketing Manager
Evan Hegarty -- Director of Manufacturing and Co-Founder
Adam Laing -- Scientist
Sudip Mondal
Shivang Sharma -- Tecnical Sales and Marketing Manager
Company News
There are no news available.
